Base de dados : MEDLINE
Pesquisa : D02.241.081.901.434 [Categoria DeCS]
Referências encontradas : 13470 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1347 ir para página                         

  1 / 13470 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29238189
[Au] Autor:Zhang CY; Sun XY; Ouyang JM; Gui BS
[Ad] Endereço:Institute of Biomineralization and Lithiasis Research, Jinan University, Guangzhou.
[Ti] Título:Diethyl citrate and sodium citrate reduce the cytotoxic effects of nanosized hydroxyapatite crystals on mouse vascular smooth muscle cells.
[So] Source:Int J Nanomedicine;12:8511-8525, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Objective: This study aimed to investigate the damage mechanism of nanosized hydroxyapatite (nano-HAp) on mouse aortic smooth muscle cells (MOVASs) and the injury-inhibiting effects of diethyl citrate (Et Cit) and sodium citrate (Na Cit) to develop new drugs that can simultaneously induce anticoagulation and inhibit vascular calcification. Methods: The change in cell viability was evaluated using a cell proliferation assay kit, and the amount of lactate dehydrogenase (LDH) released was measured using an LDH kit. Intracellular reactive oxygen species (ROS) and mitochondrial damage were detected by DCFH-DA staining and JC-1 staining. Cell apoptosis and necrosis were detected by Annexin V staining. Intracellular calcium concentration and lysosomal integrity were measured using Fluo-4/AM and acridine orange, respectively. Results: Nano-HAp decreased cell viability and damaged the cell membrane, resulting in the release of a large amount of LDH. Nano-HAp entered the cells and damaged the mitochondria, and then induced cell apoptosis by producing a large amount of ROS. In addition, nano-HAp increased the intracellular Ca concentration, leading to lysosomal rupture and cell necrosis. On addition of the anticoagulant Et Cit or Na Cit, cell viability and mitochondrial membrane potential increased, whereas the amount of LDH released, ROS, and apoptosis rate decreased. Et Cit and Na Cit could also chelate with Ca to inhibit the intracellular Ca elevations induced by nano-HAp, prevent lysosomal rupture, and reduce cell necrosis. High concentrations of Et Cit and Na Cit exhibited strong inhibitory effects. The inhibitory capacity of Na Cit was stronger than that of Et Cit at similar concentrations. Conclusion: Both Et Cit and Na Cit significantly reduced the cytotoxicity of nano-HAp on MOVASs and inhibited the apoptosis and necrosis induced by nano-HAp crystals. The chelating function of citrate resulted in both anticoagulation and binding to HAp. Et Cit and Na Cit may play a role as anticoagulants in reducing injury to the vascular wall caused by nano-HAp.
[Mh] Termos MeSH primário: Citratos/farmacologia
Durapatita/efeitos adversos
Músculo Liso Vascular/citologia
Nanopartículas/efeitos adversos
[Mh] Termos MeSH secundário: Animais
Anticoagulantes/farmacologia
Apoptose/efeitos dos fármacos
Calcinose/prevenção & controle
Cálcio/metabolismo
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Durapatita/química
Potencial da Membrana Mitocondrial/efeitos dos fármacos
Camundongos
Mitocôndrias/efeitos dos fármacos
Mitocôndrias/metabolismo
Músculo Liso Vascular/efeitos dos fármacos
Músculo Liso Vascular/metabolismo
Nanopartículas/química
Espécies Reativas de Oxigênio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Citrates); 0 (Reactive Oxygen Species); 0 (diethyl citrate); 1Q73Q2JULR (sodium citrate); 91D9GV0Z28 (Durapatite); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S145386


  2 / 13470 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29203747
[Au] Autor:Mielczarek-Puta M; Chrzanowska A; Otto-Slusarczyk D; Grabon W; Baranczyk-Kuzma A
[Ad] Endereço:Katedra I Zaklad Biochemii, Warszawski Uniwersytet Medyczny, Warszawa, Polska.
[Ti] Título:[Effect of antioxidants on human primary and metastatic colon cancer cells at hypoxia and normoxia].
[So] Source:Wiad Lek;70(5):946-952, 2017.
[Is] ISSN:0043-5147
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:THE AIM: Evaluation of some antioxidants on human colon cancer cells viability and proliferation at various oxygen levels. MATERIAL AND METHODS: Human primary (SW480) and metastatic (SW620) colon cancer cells were cultured at hypoxia (1% oxygen), tissues (10% oxygen) and atmospheric (21% oxygen) normoxia with quercetin, epigallocatechin gallate, lipoic acid, hydroxycitric acid, their mixture, and without studied compounds (control). Antioxidants were used at physiological concentrations. The cell viability was determined by trypan blue dye exclusion and proliferation by MTT assay. RESULTS: The viability of each line ranged from 80% to 97%, and it was independent on the compound and oxygen availability. At hypoxia the cell count of both lines was lower than for the controls in the presence of each studied compound. At tissue normoxia the cell count of primary cancer cells was decreased only with epigallocatechin gallate, whereas metastatic cells were sensitive for each antioxidant. CONCLUSIONS: Our results indicated, that the studied antioxidants were not cytotoxic at physiological levels for both pirmary and metastatic colon cancer. Their cytostatic effect depend on the type of cell, oxygen availability and antioxidant concentration.
[Mh] Termos MeSH primário: Antioxidantes/farmacologia
Hipóxia Celular/efeitos dos fármacos
Neoplasias do Colo/tratamento farmacológico
[Mh] Termos MeSH secundário: Catequina/análogos & derivados
Catequina/farmacologia
Linhagem Celular Tumoral/efeitos dos fármacos
Citratos/farmacologia
Neoplasias do Colo/patologia
Seres Humanos
Metástase Neoplásica
Oxigênio/farmacologia
Ácido Tióctico/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Citrates); 73Y7P0K73Y (Thioctic Acid); 8R1V1STN48 (Catechin); 8W94T9026R (hydroxycitric acid); BQM438CTEL (epigallocatechin gallate); S88TT14065 (Oxygen)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE


  3 / 13470 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29235331
[Au] Autor:Zagayko AL; Shkapo AI; Fylymonenko VP; Briukhanova TO
[Ti] Título:The impact of hydroxycitric acid on the lipid metabolism profile under experimental insulin resistance syndrome of Syrian hamsters.
[So] Source:Ukr Biochem J;88(3):78-82, 2016 May-Jun.
[Is] ISSN:2409-4943
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:The syndrome of insulin resistance (IR) is one of the leading reasons for the increased risk of cardiovascular diseases and their complications. Among the key components of IR are obesity and dyslipidemia. Hydroxycitric acid (HCA), an inhibitor of a key enzyme of lipogenesis ATP citrate lyase (ACLY) is a promising obesity treatment agent. The aim of this work was to investigate the effect of HCA on lipid and lipoproteins content in the blood serum, as well as lipid content and activity of some lipid metabolism enzymes in the liver of hamsters with IR. IR was modeled by keeping animals on high-fat diet with addition of fructose. Lipid content was determined by using standard reagent kits, the level of lipoproteins, the activity of glucose 6-phosphate dehydrogenase and ACLY ­ spectrophotometrically, lysosomal lipase activity ­ fluorimetrically. Development of hyperlipidemia and atherogenic dyslipidemia, lipid accumulation in the liver, activation of lysosomal lipase and ACLY and reduction of glucose 6-phosphate dehydrogenase activity were shown under IR. The treatment by HCA reduces the manifestations of hyperlipidemia, but enhances the lipid accumulation in the liver.
[Mh] Termos MeSH primário: Fármacos Antiobesidade/farmacologia
Citratos/farmacologia
Hiperlipidemias/tratamento farmacológico
Resistência à Insulina
Fígado/efeitos dos fármacos
Obesidade/tratamento farmacológico
[Mh] Termos MeSH secundário: ATP Citrato (pro-S)-Liase/antagonistas & inibidores
ATP Citrato (pro-S)-Liase/genética
ATP Citrato (pro-S)-Liase/metabolismo
Animais
Dieta Hiperlipídica/efeitos adversos
Frutose/efeitos adversos
Regulação da Expressão Gênica
Glucosefosfato Desidrogenase/genética
Glucosefosfato Desidrogenase/metabolismo
Hiperlipidemias/enzimologia
Hiperlipidemias/etiologia
Hiperlipidemias/patologia
Lipase/genética
Lipase/metabolismo
Metabolismo dos Lipídeos/efeitos dos fármacos
Fígado/enzimologia
Fígado/patologia
Lisossomos/efeitos dos fármacos
Lisossomos/enzimologia
Masculino
Mesocricetus
Obesidade/enzimologia
Obesidade/etiologia
Obesidade/patologia
Oxirredução
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 0 (Citrates); 30237-26-4 (Fructose); 8W94T9026R (hydroxycitric acid); EC 1.1.1.49 (Glucosephosphate Dehydrogenase); EC 2.3.3.8 (ATP Citrate (pro-S)-Lyase); EC 3.1.1.3 (Lipase)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE
[do] DOI:10.15407/ubj88.03.078


  4 / 13470 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29185591
[Au] Autor:Tuerdi B; Zuo L; Sun H; Wang K; Wang Z; Li G
[Ad] Endereço:Respiratory Intensive Care Units, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
[Ti] Título:Safety and efficacy of regional citrate anticoagulation in continuous blood purification treatment of patients with multiple organ dysfunction syndrome.
[So] Source:Braz J Med Biol Res;51(1):e6378, 2017 Nov 17.
[Is] ISSN:1414-431X
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to discuss the safety and efficacy of regional citrate anticoagulation (RCA) on continuous blood purification (CBP) during the treatment of multiple organ dysfunction syndrome (MODS). Thirty-five patients with MODS were divided into two groups: the local citrate anticoagulation (RCA) group, and the heparin-free blood purification (hfBP) group. The MODS severity was assessed according to Marshall's MODS score criteria. Blood coagulation indicators, blood pressure, filter lifespan, filter replacement frequency, anticoagulation indicators, and main metabolic and electrolyte indicators were analyzed and compared between RCA and hfBP groups. RCA resulted in lower blood pressure than hfBP. The filter efficacy in RCA treatment was longer than in the hfBP group. The blood clearance of creatine, blood urea nitrogen and uric acid was better in the RCA group. RCA also led to higher pH than hfBP. Neither treatment resulted in severe bleeding events. In addition, MODS score was positively correlated with prothrombin time and activated partial thromboplastin time but negatively correlated with platelet concentration. RCA is a safer and more effective method in CBP treatment; however, it could also lead to low blood pressure and blood alkalosis.
[Mh] Termos MeSH primário: Anticoagulantes/farmacologia
Citratos/farmacologia
Ácido Cítrico/farmacologia
Glucose/farmacologia
Hemofiltração/métodos
Insuficiência de Múltiplos Órgãos/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticoagulantes/uso terapêutico
Coagulação Sanguínea/efeitos dos fármacos
Pressão Sanguínea/efeitos dos fármacos
Citratos/uso terapêutico
Ácido Cítrico/uso terapêutico
Feminino
Glucose/uso terapêutico
Hemorragia/induzido quimicamente
Heparina/farmacologia
Heparina/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Valores de Referência
Reprodutibilidade dos Testes
Fatores de Risco
Índice de Gravidade de Doença
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Citrates); 1Q73Q2JULR (sodium citrate); 2968PHW8QP (Citric Acid); 9005-49-6 (Heparin); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE


  5 / 13470 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173321
[Au] Autor:Koch G; Datta AN; Jost K; Schulzke SM; van den Anker J; Pfister M
[Ad] Endereço:Pediatric Pharmacology and Pharmacometrics Research, University of Basel Children's Hospital (UKBB), Basel, Switzerland. Electronic address: gilbert.koch@ukbb.ch.
[Ti] Título:Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates.
[So] Source:J Pediatr;191:50-56.e1, 2017 Dec.
[Is] ISSN:1097-6833
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To identify dosing strategies that will assure stable caffeine concentrations in preterm neonates despite changing caffeine clearance during the first 8 weeks of life. METHODS: A 3-step simulation approach was used to compute caffeine doses that would achieve stable caffeine concentrations in the first 8 weeks after birth: (1) a mathematical weight change model was developed based on published weight distribution data; (2) a pharmacokinetic model was developed based on published models that accounts for individual body weight, postnatal, and gestational age on caffeine clearance and volume of distribution; and (3) caffeine concentrations were simulated for different dosing regimens. RESULTS: A standard dosing regimen of caffeine citrate (using a 20 mg/kg loading dose and 5 mg/kg/day maintenance dose) is associated with a maximal trough caffeine concentration of 15 mg/L after 1 week of treatment. However, trough concentrations subsequently exhibit a clinically relevant decrease because of increasing clearance. Model-based simulations indicate that an adjusted maintenance dose of 6 mg/kg/day in the second week, 7 mg/kg/day in the third to fourth week and 8 mg/kg/day in the fifth to eighth week assures stable caffeine concentrations with a target trough concentration of 15 mg/L. CONCLUSIONS: To assure stable caffeine concentrations during the first 8 weeks of life, the caffeine citrate maintenance dose needs to be increased by 1 mg/kg every 1-2 weeks. These simple adjustments are expected to maintain exposure to stable caffeine concentrations throughout this important developmental period and might enhance both the short- and long-term beneficial effects of caffeine treatment.
[Mh] Termos MeSH primário: Apneia/tratamento farmacológico
Cafeína/administração & dosagem
Estimulantes do Sistema Nervoso Central/administração & dosagem
Citratos/administração & dosagem
Doenças do Prematuro/tratamento farmacológico
[Mh] Termos MeSH secundário: Peso ao Nascer
Cafeína/farmacocinética
Cafeína/uso terapêutico
Estimulantes do Sistema Nervoso Central/farmacocinética
Estimulantes do Sistema Nervoso Central/uso terapêutico
Citratos/farmacocinética
Citratos/uso terapêutico
Relação Dose-Resposta a Droga
Esquema de Medicação
Monitoramento de Medicamentos
Feminino
Seres Humanos
Lactente
Recém-Nascido
Recém-Nascido Prematuro
Masculino
Ganho de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 0 (Citrates); 3G6A5W338E (Caffeine); U26EO4675Q (caffeine citrate)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  6 / 13470 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28956599
[Au] Autor:Reddick JJ; Sirkisoon S; Dahal RA; Hardesty G; Hage NE; Booth WT; Quattlebaum AL; Mills SN; Meadows VG; Adams SLH; Doyle JS; Kiel BE
[Ad] Endereço:Department of Chemistry and Biochemistry, University of North Carolina at Greensboro , Greensboro, North Carolina 27402, United States.
[Ti] Título:First Biochemical Characterization of a Methylcitric Acid Cycle from Bacillus subtilis Strain 168.
[So] Source:Biochemistry;56(42):5698-5711, 2017 Oct 24.
[Is] ISSN:1520-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The genome of Bacillus subtilis strain 168 contains the mother cell metabolic gene (mmg) operon that encodes homologues from the methylcitric acid cycle. We showed that the three genes, mmgDE and yqiQ(mmgF), provide three of the five steps of the methylcitric acid cycle. We also showed that the fourth step can be supplied by citB (aconitase), and we suggest that the fifth missing step, the propionyl-CoA synthetase, is probably skipped because the ß-oxidation of methyl-branched fatty acids by the enzymes encoded by mmgABC should produce propionyl-CoA. We also noted interesting enzymology for MmgD and MmgE. First, MmgD is a bifunctional citrate synthase/2-methylcitrate synthase with 2.3-fold higher activity as a 2-methylcitrate synthase. This enzyme catalyzes the formation of either (2S,3R)- or (2R,3S)-2-methylcitrate, but reports of 2-methylcitrate synthases from other species indicated that they produced the (2S,3S) isomer. However, we showed that MmgD and PrpC (from Escherichia coli) in fact produce the same stereoisomer. Second, the MmgE enzyme is not a stereospecific 2-methylcitrate dehydratase because it can dehydrate at least two of the four diastereomers of 2-methylcitrate to yield either (E)-2-methylaconitate or (Z)-2-methylaconitate. We also showed for the first time that the E. coli homologue PrpD exhibited the same lack of stereospecificity. However, the physiological pathways proceed via (Z)-2-methylaconitate, which served as the substrate for the citB enzyme in the synthesis of 2-methylisocitrate. We completed our characterization of this pathway by showing that the 2-methylisocitrate produced by CitB is converted to pyruvate and succinate by the enzyme YqiQ(MmgF).
[Mh] Termos MeSH primário: Bacillus subtilis/metabolismo
Citratos/metabolismo
Óperon/fisiologia
Oxo-Ácido-Liases/metabolismo
[Mh] Termos MeSH secundário: Bacillus subtilis/genética
Escherichia coli/genética
Escherichia coli/metabolismo
Proteínas de Escherichia coli/genética
Proteínas de Escherichia coli/metabolismo
Hidroliases/genética
Hidroliases/metabolismo
Oxirredução
Oxo-Ácido-Liases/genética
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Citrates); 0 (Escherichia coli Proteins); 6061-96-7 (2-methylcitric acid); EC 2.3.3.5 (2-methylcitrate synthase); EC 4.1.3.- (Oxo-Acid-Lyases); EC 4.2.1.- (Hydro-Lyases); EC 4.2.1.79 (methylcitrate dehydratase, E coli)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170929
[St] Status:MEDLINE
[do] DOI:10.1021/acs.biochem.7b00778


  7 / 13470 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28954258
[Au] Autor:Li L; Peng M; Ge C; Yu L; Ma H
[Ti] Título:(-)-Hydroxycitric Acid Reduced Lipid Droplets Accumulation Via Decreasing Acetyl-Coa Supply and Accelerating Energy Metabolism in Cultured Primary Chicken Hepatocytes.
[So] Source:Cell Physiol Biochem;43(2):812-831, 2017.
[Is] ISSN:1421-9778
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: (-)-Hydroxycitric acid (HCA) had been shown to suppress fat accumulation in animals and humans, while the underlying biochemical mechanism is not fully understood, especially little information is available on whether (-)-HCA regulates energy metabolism and consequently affects fat deposition. METHODS: Hepatocytes were cultured for 24 h and then exposed to (-)-HCA (0, 1, 10, 50 µM), enzyme protein content was determined by ELISA; lipid metabolism gene mRNA levels were detected by RT-PCR. RESULTS: (-)-HCA significantly decreased the number and total area of lipid droplets. ATP-citrate lyase, fatty acid synthase and sterol regulatory element binding protein-1c mRNA level were significantly decreased after (-)-HCA treatment, whereas peroxisome proliferator-activated receptor α mRNA level was significantly increased. (-)-HCA significantly decreased ATP-citrate lyase activity and acetyl-CoA content in cytosol, but significantly increased glucose consumption and mitochondrial oxygen consumption rate. (-)-HCA promoted the activity/content of glucokinase, phosphofructokinase-1, pyruvate kinase, pyruvate dehydrogenase, citrate synthase, aconitase, succinate dehydrogenase, malate dehydrogenase, NADH dehydrogenase and ATP synthase remarkably. CONCLUSIONS: (-)-HCA decreased lipid droplets accumulation by reducing acetyl-CoA supply, which mainly achieved via inhibition of ATP-citrate lyase, and accelerating energy metabolism in chicken hepatocytes. These results proposed a biochemical mechanism of fat reduction by (-)-HCA in broiler chickens in term of energy metabolism.
[Mh] Termos MeSH primário: Acetilcoenzima A/metabolismo
Galinhas/metabolismo
Citratos/metabolismo
Metabolismo Energético
Hepatócitos/metabolismo
Gotículas Lipídicas/metabolismo
Metabolismo dos Lipídeos
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Citrates); 72-89-9 (Acetyl Coenzyme A); 8W94T9026R (hydroxycitric acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1159/000481564


  8 / 13470 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28915261
[Au] Autor:Monostori P; Klinke G; Richter S; Baráth Á; Fingerhut R; Baumgartner MR; Kölker S; Hoffmann GF; Gramer G; Okun JG
[Ad] Endereço:Department of General Pediatrics, Division of Neuropediatrics and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
[Ti] Título:Simultaneous determination of 3-hydroxypropionic acid, methylmalonic acid and methylcitric acid in dried blood spots: Second-tier LC-MS/MS assay for newborn screening of propionic acidemia, methylmalonic acidemias and combined remethylation disorders.
[So] Source:PLoS One;12(9):e0184897, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: Increased propionylcarnitine levels in newborn screening are indicative for a group of potentially severe disorders including propionic acidemia (PA), methylmalonic acidemias and combined remethylation disorders (MMACBL). This alteration is relatively non-specific, resulting in the necessity of confirmation and differential diagnosis in subsequent tests. Thus, we aimed to develop a multiplex approach for concurrent determination of 3-hydroxypropionic acid, methylmalonic acid and methylcitric acid from the same dried blood spot (DBS) as in primary screening (second-tier test). We also set out to validate the method using newborn and follow-up samples of patients with confirmed PA or MMACBL. METHODS: The assay was developed using liquid chromatography-tandem mass spectrometry and clinically validated with retrospective analysis of DBS samples from PA or MMACBL patients. RESULTS: Reliable determination of all three analytes in DBSs was achieved following simple and fast (<20 min) sample preparation without laborious derivatization or any additional pipetting steps. The method clearly distinguished the pathological and normal samples and differentiated between PA and MMACBL in all stored newborn specimens. Methylcitric acid was elevated in all PA samples; 3-hydroxypropionic acid was also high in most cases. Methylmalonic acid was increased in all MMACBL specimens; mostly together with methylcitric acid. CONCLUSIONS: A liquid chromatography-tandem mass spectrometry assay allowing simultaneous determination of the biomarkers 3-hydroxypropionic acid, methylmalonic acid and methylcitric acid in DBSs has been developed. The assay can use the same specimen as in primary screening (second-tier test) which may reduce the need for repeated blood sampling. The presented preliminary findings suggest that this method can reliably differentiate patients with PA and MMACBL in newborn screening. The validated assay is being evaluated prospectively in a pilot project for extension of the German newborn screening panel (?Newborn screening 2020"; Newborn Screening Center, University Hospital Heidelberg).
[Mh] Termos MeSH primário: Erros Inatos do Metabolismo dos Aminoácidos/sangue
Citratos/sangue
Teste em Amostras de Sangue Seco/métodos
Ácido Láctico/análogos & derivados
Programas de Rastreamento/métodos
Ácido Metilmalônico/sangue
Acidemia Propiônica/sangue
[Mh] Termos MeSH secundário: Cromatografia Líquida/métodos
Feminino
Seres Humanos
Recém-Nascido
Ácido Láctico/sangue
Masculino
Espectrometria de Massas/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Citrates); 33X04XA5AT (Lactic Acid); 6061-96-7 (2-methylcitric acid); 8LL8S712J7 (Methylmalonic Acid); C4ZF6XLD2X (hydracrylic acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170916
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184897


  9 / 13470 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28818800
[Au] Autor:Johnson SA; Walsh A; Brown MR; Lute SC; Roush DJ; Burnham MS; Brorson KA
[Ad] Endereço:DBRRII, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA. Electronic address: sarah.johnson1@fda.hhs.gov.
[Ti] Título:The step-wise framework to design a chromatography-based hydrophobicity assay for viral particles.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1061-1062:430-437, 2017 Sep 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A high-salt, hydrophobic interaction chromatography (HIC) method was developed to measure the relative hydrophobicity of a diverse set of solutes. Through the careful control of buffer pH and salt concentration, this assay was then used to ascertain for the first time the relative hydrophobicity values of three different bacteriophage, four mammalian viruses, and a range of biotech medicinal proteins as benchmarked to protein standards previously characterized for hydrophobicity.
[Mh] Termos MeSH primário: Cromatografia Líquida/métodos
Vírion/isolamento & purificação
[Mh] Termos MeSH secundário: Sulfato de Amônio/química
Biotecnologia
Citratos/química
Concentração de Íons de Hidrogênio
Interações Hidrofóbicas e Hidrofílicas
Cultura de Vírus
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Citrates); 1Q73Q2JULR (sodium citrate); SU46BAM238 (Ammonium Sulfate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170819
[St] Status:MEDLINE


  10 / 13470 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28800620
[Au] Autor:Zhang Y; Fang S; Dai J; Zhu L; Fan H; Tang W; Fan Y; Dai H; Zhang P; Wang Y; Xing X; Yang C
[Ad] Endereço:Department of Plastic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, PR China.
[Ti] Título:Experimental study of ASCs combined with POC-PLA patch for the reconstruction of full-thickness chest wall defects.
[So] Source:PLoS One;12(8):e0182971, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To explore the repairing effect of combination of adipose stem cells (ASCs) and composite scaffolds on CWR, the electrospun Poly 1, 8-octanediol-co-citric acid (POC)-poly-L-lactide acid (PLA) composite scaffolds were prepared, followed by in vitro and in vivo biocompatibility evaluation of the scaffolds. Afterwards, ASCs were seeded on POC-PLA to construct the POC-PLA-ASCs scaffolds, and the POC-PLA, POC-PLA-ASCs, and traditional materials expanded polytetrafluoroethylene (ePTFE) were adopt for CWR in New Zealand white (NZW) rabbit models. As results, the POC-PLA-ASCs patches possessed good biocompatibility as the high proliferation ability of cells surrounding the patches. Rabbits in POC-PLA-ASCs groups showed better pulmonary function, less pleural adhesion, higher degradation rate and more neovascularization when compared with that in other two groups. The results of western blot indicated that POC-PLA-ASCs patches accelerated the expression of VEGF and Collagen I in rabbit models. From the above, our present study demonstrated that POC-PLA material was applied for CWR successfully, and ASCs seeded on the sheets could improve the pleural adhesions and promote the reparation of chest wall defects.
[Mh] Termos MeSH primário: Citratos/farmacologia
Anormalidades Congênitas/reabilitação
Poliésteres/farmacologia
Polímeros/farmacologia
Células-Tronco/fisiologia
Parede Torácica/cirurgia
Tecidos Suporte
[Mh] Termos MeSH secundário: Tecido Adiposo/citologia
Tecido Adiposo/fisiologia
Animais
Biomarcadores/metabolismo
Terapia Baseada em Transplante de Células e Tecidos/métodos
Células Cultivadas
Citratos/química
Colágeno Tipo I/genética
Colágeno Tipo I/metabolismo
Anormalidades Congênitas/patologia
Anormalidades Congênitas/cirurgia
Feminino
Expressão Gênica
Masculino
Neovascularização Fisiológica/efeitos dos fármacos
Poliésteres/química
Polímeros/química
Politetrafluoretileno/química
Politetrafluoretileno/farmacologia
Coelhos
Ratos
Ratos Sprague-Dawley
Células-Tronco/citologia
Telas Cirúrgicas
Parede Torácica/anormalidades
Engenharia Tecidual/métodos
Fator A de Crescimento do Endotélio Vascular/genética
Fator A de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Citrates); 0 (Collagen Type I); 0 (Polyesters); 0 (Polymers); 0 (Vascular Endothelial Growth Factor A); 0 (poly(1,8-octanediol citrate)); 459TN2L5F5 (poly(lactide)); 9002-84-0 (Polytetrafluoroethylene)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182971



página 1 de 1347 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde